| Bioactivity | JNK-IN-19 (Compound Q8) is a c-Jun N-terminal kinase inhibitor that is used for treating and/or preventing an injury before, during, or after a surgical procedure[1]. |
| CAS | 3059122-56-1 |
| Formula | C22H24F3N6Na2O6P |
| Molar Mass | 602.41 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. SATOH Yoshi, et al. PREVENTION/TREATMENT OF ISCHEMIC REPERFUSION INJURY. WO2024211291. 2024 October 10. |
JNK-IN-19
CAS: 3059122-56-1 F: C22H24F3N6Na2O6P W: 602.41
JNK-IN-19 (Compound Q8) is a c-Jun N-terminal kinase inhibitor that is used for treating and/or preventing an injury bef
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.